Physician profile
Mark G Issa
NPI 1053313346
$1,239.42
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $987 · 2020: $150 · 2022: $102.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $213.97 | 2019-2020 | |
| Astellas Pharma US INC | $206.92 | 2019 | |
| Janssen Pharmaceuticals, INC | $190.87 | 2019-2020 | |
| Amarin Pharma, INC. | $142.47 | 2019 | |
| Medtronic, INC. | $101.77 | 2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $62.31 | 2019 | |
| Pfizer INC. | $60.52 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $56.54 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $45.60 | 2019-2020 | |
| Amgen INC. | $44.69 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $37.88 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $36.69 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $23.84 | 2019 | |
| Lundbeck LLC | $15.35 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Issa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.